

P&T Motion History
Long-Acting Insulins for Type 1 and Type 2 Diabetes

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
insulin detemir insulin degludec insulin degludec/ insulin aspart insulin glargine	<p>After considering the evidence of safety, efficacy and special populations for the treatment of type 1 and type 2 diabetes, I move that insulin detemir, insulin glargine, insulin degludec, and insulin degludec/ insulin aspart combination are safe and efficacious for the treatment of their approved indications. Single agent long-acting insulins can be subject to therapeutic interchange in the Washington preferred drug list.</p> <p>Motion: Figueroa 2nd: Sanderson</p>	October 20, 2021	NA	Yes Schwilke Storhaug	Passed unanimous

Bold =new this review